Authors

Latest:

Dr Hogen on Survival Outcomes With Neoadjuvant Chemotherapy and ICS in Epithelial Ovarian Cancer

Liat Hogen, MD, FRCSC, discusses the survival outcomes achieved with interval cytoreductive surgery following neoadjuvant chemotherapy in a study of patients with initial unresectable stage IV ovarian cancer.

Oleg Gluz, MD

Oleg Gluz, MD, is chief physician of Breast Cancer Niederrhein

Latest:

Dr Gluz on Ongoing Evaluations of De-Escalated Neoadjuvant Therapy in HR+/HER2+ Breast Cancer

Oleg Gluz, MD, discusses research assessing de-escalated chemotherapy and endocrine therapy combinations in HR-positive, HER2-positive early breast cancer.

Yoshiaki Nakamura, MD, PhD

Latest:

Concluding Remarks for the Current Use of ctDNA Testing for Treatment Decisions in stage II-III CRC

Yoshiaki Nakamura, MD, PhD, discusses the quantification threshold for tissue-free ctDNA in detecting residual tumor fractions, highlights additional mutations and hypermethylated loci identified by epigenomic assays, and examines how these assays complement current radiographic monitoring in stage II to III CRC while also considering their evolving role in identifying MRD to enhance recurrence-free survival.

Angela Tatiana Alistar, MD

Latest:

Dr. Alistar on the Need to Develop Biomarkers in Pancreatic Cancer

Angela Tatiana Alistar, MD, discusses the need to develop biomarkers in pancreatic cancer.

Frank Worden, MD

Latest:

Treating BRAF V600 and NTRK Gene Fusion Positivity

Amin Nassar, MD

Latest:

Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors

Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.

Albert Grinshpun, MD, MSc

Latest:

Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer

Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.

Patricia Lugar, MD, MS, Duke Health

Latest:

Unmet Needs in SM Treatment

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

Rachel Kaufmann, PharmD

Latest:

LAG-3 Fills a Complex Role in the Immune System

The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.

Alan Tan, MD

Alan Tan, MD, is an associate professor of medicine in the Division of Hematology Oncology at Vanderbilt University Medical Center and a genitourinary oncology and melanoma specialist at Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

Latest:

Integrating ctDNA-Based MRD Testing in MIBC

The Signara assay enhances mutation tracking in urothelial cancer, improving patient outcomes through informed treatment decisions and timely interventions.

Guenther Koehne, MD, PhD

Guenther Koehne, MD, deputy director and chief of Stem Cell Transplantation, Hematologic Oncology and Benign Hematology at Miami Cancer Institute, Baptist Health South Florida

Latest:

Dr Koehne on the Evolution of the Multiple Myeloma Treatment Paradigm

Guenther Koehne, MD, discusses the roles of ASCT, CAR T-cell therapy, and bispecific antibodies in the treatment of patients with multiple myeloma.

Daniele Robesti, MD

Latest:

Dr. Robesti on Optimizing Patient Selection for Salvage Lymph Node Dissection in Prostate Cancer

Daniele Robesti, MD, discusses how to optimize patient selection for salvage lymph node dissection in prostate cancer.

Philippe E. Spiess, MD, MS, FACS

Latest:

Dr. Spiess on Key Updates in the Management of Penile Cancer

Philippe E. Spiess, MD, MS, FACS, shares key updates in the management of patients with penile cancer.

Jan Joseph Melenhorst, BSc, MS, PhD

Latest:

Dr Melenhorst on the Evolving Understanding of CAR T-Cell Therapies in CLL

Jan Joseph Melenhorst, PhD, discusses the evolving understanding of the use of CAR T-cell therapies in the treatment of patients with chronic lymphocytic leukemia.

Boyu Hu, MD

Latest:

BTK Degraders and Other Targets in Mantle Cell Lymphoma

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

Matthew Wagar, MD

Matthew Wagar, MD, is a gynecologic oncology fellow in the Department of Obstetrics and Gynecology at the University of Wisconsin School of Medicine and Public Health.

Latest:

Dr Wagar on the Use of T-DXd in Patients With HER2+ Endometrial Cancer

Matthew Wagar, MD, discusses the addition of T-DXd to the HER2-positive endometrial cancer treatment paradigm.

Eleni Efstathiou, MD, PhD, MD Anderson Cancer Center

Latest:

Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPC

Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.

Kristin K. Zorn, MD

Latest:

PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian Cancer

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

Bertrand Arnulf, MD, PhD

Latest:

Dr Arnulf on Managing Tumor Burden for Improved PFS With Ide-Cel in R/R Myeloma

Bertrand Arnulf, MD, PhD, discusses the importance of managing tumor burden for improved outcomes with ide-cel in relapsed/refractory multiple myeloma.

Miguel Villalona-Calero, MD

Latest:

Dr Villalona-Calero on the Investigation of KB-0742 in Relapsed/Refractory Solid Tumors

Miguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma and highlights the ongoing evaluation of the agent’s safety.